Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Cumberland Pharmaceuticals (CPIX) announced plans to submit an NDA to FDA for ifetroban as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). FDA granted the company’s request for rolling submission, allowing completed application sections to be submitted for review before the full application. Cumberland proposes the FIGHT DMD Phase 2 study, combined with comparison data from two natural-history databases, as pivotal evidence.
In the 12-month trial, high-dose ifetroban resulted in a 5.4% absolute improvement in left ventricular ejection fraction versus control (p=0.002). Cumberland says it plans to seek approval without additional trials, although FDA previously suggested a Phase 3 trial and raised questions about the endpoint, comparator, and statistical analysis plan. The company is analyzing 24- and 36-month cardiac MRI data from the open-label extension for possible inclusion.
Cumberland Pharmaceuticals (CPIX) added an omitted press release reporting top-line results from its 12-month Phase 2a ASSIST-SSc trial of oral ifetroban in systemic sclerosis. Ifetroban was generally well tolerated, with a safety profile consistent with prior experience. Thirty-one subjects received ifetroban and 10 received placebo. Gastrointestinal adverse events were more frequent with ifetroban, mostly mild and resolved; a modest increase in bleeding-related events was also observed, predominantly mild. No serious adverse event during treatment was assessed by the medical monitor as related to study drug.
The trial was not designed or powered to evaluate efficacy, and its sample size and exploratory analysis preclude efficacy conclusions. Cumberland plans to submit the clinical study report to the FDA, complete biomarker studies and evaluate cardiac imaging from patients in the open-label extension; those findings will inform its decision on further development.
CUMBERLAND PHARMACEUTICALS INC. (CPIX) completed the sale of its commercial product business to Apotex affiliates on July 1, 2026, for $100 million in cash, with inventory reimbursement of up to $9 million over the following 12 months. It recorded an $81.1 million disposal gain and third-quarter net income attributable to common shareholders of $77,776,986, while continuing operations lost $1,122,071. Third-quarter revenue was $2,156,356, including $1,950,000 in transition-services revenue; sales from the divested brands are classified as discontinued operations.
At September 30, 2026, cash and cash equivalents were $80,581,021. Cumberland repaid approximately $5.2 million on its revolving credit facility and paid a $1.50-per-share special dividend totaling $22.5 million. It retained its development programs and majority ownership in Cumberland Emerging Technologies. Cumberland plans an NDA submission for ifetroban in DMD-associated cardiomyopathy, and the FDA granted rolling review. The FIGHT DMD Phase 2 study reported a 5.4 percentage-point improvement in left ventricular ejection fraction for the high-dose group versus a combined control group of placebo-treated and propensity-score-matched natural-history patients.
Cumberland Pharmaceuticals reported third-quarter 2026 net income of $77.8 million, including an $81.1 million gain on disposal tied to its July 1, 2026 strategic transaction with Apotex Health. The transaction closed with $100 million in proceeds; Cumberland's commercial brands and organization were integrated into Apotex's U.S. branded business. Total revenue was $2.16 million versus $171,821 in Q3 2025; continuing operations recorded a $1.12 million net loss.
At September 30, 2026, cash and cash equivalents were $80.6 million, total assets were $113.8 million, liabilities were $41.6 million and shareholders' equity was $72.5 million. In the first nine months, operating activities used $942,253 in cash, versus $4.93 million provided in 2025.
Cumberland plans to submit an NDA for ifetroban for DMD cardiomyopathy; the FDA granted rolling review, allowing completed sections to be submitted before the full application. In the Phase 2 FIGHT DMD trial, the high-dose group showed a statistically significant 5.4-percentage-point improvement in left ventricular ejection fraction versus a control group combining placebo-treated patients with propensity score-matched natural-history patients (p=0.002). In the Phase 2a systemic sclerosis trial, no serious adverse event during 12-month treatment was assessed as related to ifetroban; planned biomarker and cardiac-imaging analyses will inform the company's decision on further development.
Cumberland Pharmaceuticals Inc. (CPIX) plans to submit an NDA to the FDA for ifetroban as a treatment for Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The FDA granted rolling review, which permits completed application sections to be submitted before the full NDA.
Cumberland proposes the FIGHT DMD Phase 2 study, together with data from two DMD natural-history databases, as the basis for approval. In the 12-month study, high-dose ifetroban produced a statistically significant 5.4% absolute improvement in left ventricular ejection fraction versus the combined placebo and propensity score-matched natural-history control (p=0.002). The FDA had suggested a Phase 3 trial and raised questions about the endpoint, comparator and statistical analysis plan; it requested additional analysis and supporting information and expressed concern about whether the proposed package would establish substantial evidence of efficacy. Long-term safety data through up to 36 months showed no treatment-related serious adverse events or new safety concerns. Cumberland says there is no assurance the FDA will file or approve the NDA.
Cumberland Pharmaceuticals Inc. (CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis. The company said the results support ifetroban’s safety and tolerability in this rare-disease population.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reports that its Board of Directors has set the frequency of advisory shareholder votes on compensation of the Company’s named executive officers at every three years, following the 2026 Annual Meeting where the three-year option received the highest number of votes.
The Board states that these advisory votes will occur every three years until the next required shareholder advisory vote on the frequency of future executive compensation votes, which must be held every six years.
CUMBERLAND PHARMACEUTICALS INC (CPIX) reported under Regulation FD that long-term safety and efficacy data from the ongoing open-label extension of its Phase 2 FIGHT DMD trial of ifetroban for Duchenne muscular dystrophy–related heart disease are not yet available.
The company had previously indicated this extension data was expected in August 2026 but now states it no longer expects to present the data in August 2026 and plans to present it at a future date when available. Cumberland also reiterates that forward-looking statements are subject to various risks and uncertainties described in its SEC filings.
Cumberland Pharmaceuticals Inc. executed a major strategic shift, completing on July 1, 2026 the sale of its FDA‑approved branded products to Apotex for $100 million in cash, plus up to $9 million of inventory reimbursement and approximately $2 million for transition services. The company will now operate as a development‑stage biopharmaceutical business focused on its ifetroban clinical programs and early‑stage candidates at Cumberland Emerging Technologies.
For the six months ended June 30, 2026, net revenues from continuing operations were $330,308 and the net loss from continuing operations was $5,962,447. Including discontinued operations, net loss attributable to common shareholders was $7,566,016, compared with net income of $516,328 in the prior‑year period, reflecting weaker results from the divested brand portfolio.
Cash and cash equivalents were $3,862,402 at June 30, 2026, before receipt of Apotex proceeds and repayment of the $5.2 million revolving credit facility. Management states that cash on hand, the $100 million transaction proceeds and inventory reimbursement will fund operations for at least twelve months. The board declared a special cash dividend of $1.50 per share, totaling $22.5 million, and authorized a new $5 million share repurchase program.
Cumberland Pharmaceuticals Inc. reported results for the three and six months ended June 30, 2026 and described a major strategic shift following the closing of its Strategic Transaction with Apotex Health. Apotex acquired Cumberland’s portfolio of FDA-approved brands and related commercial organization for $100 million in cash at closing, plus $11 million in funding for inventory and transition services, as Cumberland transitions to a development-stage biopharmaceutical company focused on rare diseases and other unmet needs.
The Board declared a $1.50 per-share special cash dividend, paid July 31, 2026 to shareholders of record July 23, 2026, after determining the company would retain significant liquidity for its pipeline and operations. For Q2 2026, the loss from continuing operations was $3.1 million, and including discontinued operations the net loss was $4.1 million.
At June 30, 2026, total assets were $62.9 million, including $3.9 million in cash and cash equivalents, with liabilities of $45.8 million and shareholders’ equity of $17.4 million$5.2 million payment and continues to advance four Phase 2 ifetroban programs, including updated Duchenne muscular dystrophy and cancer metastasis data.